N-甲基(2-甲基嘧啶-5-基)甲胺 | 1248406-79-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-甲基(2-甲基嘧啶-5-基)甲胺
• 英文名称: N-methyl-1-(2-methylpyrimidin-5-yl)methanamine
• 英文别名: N-methyl-1-(2-methylpyrimidin-5-yl)methylamine
• CAS: 1248406-79-2
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: MKXZINXDIQPONN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-甲基(2-甲基嘧啶-5-基)甲胺 、 ethyl 6-bromo-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  4-Oxo-1-芳基-1,4-二氢喹啉-3-羧酰胺作为代谢型谷氨酸受体亚型2的选择性负变构调节剂的设计。

  摘要：

  II组代谢型谷氨酸受体（mGlus）的正构和变构拮抗剂都已被用于建立mGlu2 / 3抑制与多种中枢神经系统疾病和病症之间的联系。尽管与mGlu家族的其余六个成员相比，这些工具通常对mGlu2 / 3具有良好的选择性，但事实证明，仅对单独的II类mGlus之一具有选择性的化合物。在本文中，我们报道了从一系列4-氧-1-芳基-1,4-二氢喹啉-3-羧酰胺中发现的有效且高度选择性的mGlu2负变构调节剂58（VU6001192）。该系列的设计思想集中在将专利文献中最近公开的喹啉系列转变为先前用于制备毒蕈碱型乙酰胆碱受体亚型1阳性变构调节剂的化学型。化合物58表现出良好的特性，将成为了解选择性抑制CNS中mGlu2的生物学意义的有用工具。

  DOI：

  10.1021/acs.jmedchem.5b01371

文献信息

• Nuclear Transport Modulators and Uses Thereof
  申请人：Sandanayaka Vincent P.

  公开号：US20150018332A1

  公开（公告）日：2015-01-15

  The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  本发明通常涉及核转运调节剂，例如CRM1抑制剂，更具体地涉及公式（I）所表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述。本发明还包括合成和使用结构式（I）的化合物，或其药学上可接受的盐或组合物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况中的使用。
• Nuclear transport modulators and uses thereof
  申请人：Sandanayaka Vincent P.

  公开号：US09428490B2

  公开（公告）日：2016-08-30

  The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  本发明通常涉及核运输调节剂，例如CRM1抑制剂，更具体地涉及由公式（I）表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述的那样。本发明还包括合成和使用结构式（I）的化合物，或其药学上可接受的盐或组成物，例如在治疗、调节和/或预防与CRM1活性相关的生理状况中的应用。
• N-(HETEROCYCLE-METHYL)ALKYLAMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND BACTERICIDE
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1391450A1

  公开（公告）日：2004-02-25

  A N-heterocyclicmethyl-alkylamine derivative according to the present invention is a N-heterocyclicmethyl-alkylamine derivative represented by the following general formula (I): or an acid addition salt thereof. [in the formula, R1 represents a heterocycle which has at least one nitrogen atom as a hetero atom and may have a substituent on a ring; R2 represents a hydrogen or the like; R3 represents an alkyl group having a carbon number of 1 to 5 or the like; R4 represents an alkyl group having a carbon number of 1 to 5 or the like; when R4 is an alkyl group having a carbon number of 1 to 5 or a halogenated alkyl group having a carbon number of 1 to 5, carbon atoms in R3 and R4 may be bonded to form a ring structure; m represents an integer of 1 to 3; R5 represents a cycloalkyl group or the like described by the following formula (III): (in the formula, Y and Z each represents a hydrogen atom or the like, the letter p represents an integer of 2 to 5, and the groups described by CYZ may be each the same or different), when m is 1 and R4 is a hydrogen atom, R5 is a cycloalkyl group describedby the foregoing formula (III).]

  根据本发明，N-杂环甲基-烷基胺衍生物是由以下通式（I）代表的 N-杂环甲基-烷基胺衍生物： 或其酸加成盐。 [式中，R1 代表杂环，该杂环至少有一个氮原子作为杂原子，并可在环上有取代基；R2 代表氢或类似物；R3 代表碳原子数为 1 至 5 的烷基或类似物；R4 代表碳原子数为 1 至 5 的烷基或类似物；当 R4 是碳原子数为 1 至 5 的烷基或碳原子数为 1 至 5 的卤代烷基时，R3 和 R4 中的碳原子可以键合形成环状结构；m 代表 1 至 3 的整数；R5 代表下式（III）所述的环烷基或类似基团： (式中，Y 和 Z 分别代表氢原子或类似物，字母 p 代表 2 至 5 的整数，CYZ 所述基团可以相同或不同)，当 m 为 1 且 R4 为氢原子时，R5 为前式(III)所述的环烷基]。
• N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide
  申请人：Ito Atsushi

  公开号：US20050101783A1

  公开（公告）日：2005-05-12

  A N-heterocyclicmethyl-alkylamine derivative according to the present invention is a N-heterocyclicmethyl-alkylamine derivative represented by the following general formula (I): or an acid addition salt thereof. [in the formula, R 1 represents a heterocycle which has at least one nitrogen atom as a hetero atom and may have a substituent on a ring; R 2 represents a hydrogen or the like; R 3 represents an alkyl group having a carbon number of 1 to 5 or the like; R 4 represents an alkyl group having a carbon number of 1 to 5 or the like; when R 4 is an alkyl group having a carbon number of 1 to 5 or a halogenated alkyl group having a carbon number of 1 to 5, carbon atoms in R 3 and R 4 may be bonded to form a ring structure; m represents an integer of 1 to 3; R 5 represents a cycloalkyl group or the like described by the following formula (III): (in the formula, Y and Z each represents a hydrogen atom or the like, the letter p represents an integer of 2 to 5, and the groups described by CYZ may be each the same or different), when m is 1 and R 4 is a hydrogen atom, R 5 is a cycloalkyl group described by the foregoing formula (III).]

  根据本发明，N-杂环甲基-烷基胺衍生物是由以下通式（I）代表的 N-杂环甲基-烷基胺衍生物： 或其酸加成盐。 [式中，R 1 代表至少有一个氮原子作为杂原子的杂环，并可在环上有取代基；R 2 代表氢或类似物；R 3 代表碳原子数为 1 至 5 的烷基或类似物； R 4 代表碳原子数为 1 至 5 的烷基或类似物；当 R 4 是碳原子数为 1 至 5 的烷基或碳原子数为 1 至 5 的卤代烷基时，R 3 和 R 4 中的碳原子可以键合形成环状结构；m 代表 1 至 3 的整数；R 5 代表下式（III）所述的环烷基或类似基团： (式中，Y 和 Z 分别代表氢原子或类似物，字母 p 代表 2 至 5 的整数，CYZ 所述基团可以相同或不同），当 m 为 1 且 R 4 是氢原子时，R 5 是前述式 (III) 所述的环烷基]。
• NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
  申请人：Karyopharm Therapeutics, Inc.

  公开号：EP2736883A1

  公开（公告）日：2014-06-04